CYTOFOTCPharmaceutical PreparationsFiscal year ends December 31
Altamira Therapeutics Ltd.
Financials through fiscal 2024, year ended Dec 31, 2024Last filing: 20-F on Apr 30, 2025
$0.09+0.00 (0.00%)
Close on Oct 19, 2026
Margins
Share of revenue, fiscal years 2014 to 2024
Gross margin
–
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2024
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2015 | FY2019 | FY2024 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | – | |
| Return on assets | – | -69.4% | – | |
| Current ratio | – | 1.04 | – | |
| Interest coverage | -46.1× | -4.6× | – | |
| Diluted shares | 0M | 0M | 0M |
Cash use needs five years of cash flow figures
Altamira Therapeutics does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-1020890.0%
×Asset turnover0.00×
×Equity multiplier-7.54×
=Return on equity, FY2023416.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2023 | -1020890.0% | 0.00× | -7.54× | 416.9% |
| FY2022 | -8680.3% | 0.02× | 5.40× | -1123.7% |
| FY2021 | -26703.1% | 0.00× | 1.34× | -114.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2024 against fiscal 2023
0of 1 tests passed in fiscal 2024. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero–
- Return on assets improvedROA up on the prior year-61.4% → –
- Earnings backed by cashOperating cash flow above net income– vs –
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.38 → –
- No dilutionShare count did not rise0M → 0M
- Gross margin improvedGross margin up on the prior year-8862.27% → –
- More efficientAsset turnover rose0.00 → –